Pivotal Therapeutics Inc.
CNSX : PVO

Pivotal Therapeutics Inc.

February 22, 2012 11:34 ET

Pivotal Therapeutics Files Five International Patent Applications

WOODBRIDGE, ONTARIO--(Marketwire - Feb. 22, 2012) - Pivotal Therapeutics Inc. (CNSX:PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health, announced today that it has filed five international patent applications under the Patent Cooperation Treaty (PCT), directed toward its novel lead product VASCAZEN™, and combinations thereof with certain cardiovascular treatment agents. The PCT is an international patent application. A PCT application has the effect of a national application for a patent in any of the 142 designated PCT countries, and thereby secures patent pending status for VASCAZEN™ in all the designated countries. This filing follows from the Provisional Patent filings of last year, adding significant data demonstrating the unique properties of VASCAZEN™.

"The filing of these PCT patent applications is a critical step in Pivotal's strategy for securing global Intellectual Property rights for VASCAZEN™" says Rachelle MacSweeney, President of Pivotal Therapeutics. "These filings represent the culmination of research conducted over the last several years which quantify the unique properties of our product's ultra high purity prescription-grade Omega-3 formulation in meeting the dietary Omega-3 deficient needs of patients with cardiovascular disease, by elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with a reduced risk of cardiovascular complications".

By ensuring that VASCAZEN's™ unique EPA to DHA ratio fish oils are of the highest purity, Pivotal Therapeutics is able to maximize the correction of the dietary deficiency provided by VASCAZEN™ either alone or in combination with other active ingredients in cardiovascular patients.

"Pivotal's latest patent filings create value while demonstrating its dedication to producing novel prescription medical food products that further the goal of continuing to develop cutting edge medical foods for the dietary management of patients with a variety of metabolic deficiencies," says Dr. George Jackowski, Chief Scientific Officer & Chair of Pivotal Therapeutics.

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (CNSX:PVO) specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.

OMAZEN is a >90% pure, proprietary EPA:DHA fatty acid formulation commercialized for sale and distribution in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels. The unique formulation and dosage will be available to patients and consumers who realize the health benefits of Omega-3 supplementation with a quality product.

VASCAZEN is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending US and foreign patents and commercialized by prescription only. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.

Disclosure Notice

The information contained in this document is as of February 22, 2012. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments.

Contact Information